GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adcock Ingram Holdings Ltd (JSE:AIP) » Definitions » Net Income Including Noncontrolling Interests

Adcock Ingram Holdings (JSE:AIP) Net Income Including Noncontrolling Interests : R874 Mil (TTM As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Adcock Ingram Holdings Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Adcock Ingram Holdings's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2023 was R444 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was R874 Mil.


Adcock Ingram Holdings Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Adcock Ingram Holdings's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adcock Ingram Holdings Net Income Including Noncontrolling Interests Chart

Adcock Ingram Holdings Annual Data
Trend Sep13 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 695.42 682.19 662.11 800.73 898.36

Adcock Ingram Holdings Semi-Annual Data
Mar14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 392.17 408.56 468.35 430.01 444.17

Adcock Ingram Holdings Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was R874 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adcock Ingram Holdings Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Adcock Ingram Holdings's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Adcock Ingram Holdings (JSE:AIP) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1 New Road, (c/o New Road & 7th Street), Midrand, Johannesburg, GT, ZAF, 1682
Adcock Ingram Holdings Ltd is a drug manufacturing company. The company manufactures, markets, and distributes a wide range of healthcare products. The company generates roughly two-thirds of its sales from the private sector, with the remaining from the public sector. Adcock operates in four broad areas: renal disease, medicine delivery, transfusion therapies, and blood and specialized pharmaceuticals. The company generates the vast majority of its revenue in southern Africa, followed by the rest of Africa and India.